“Utah is taking a major step toward allowing artificial intelligence to handle certain medical prescriptions without requiring a doctor to review every individual decision... Under Utah's regulatory approach, approved AI systems may be permitted to operate within carefully defined medical services... One potential application is renewing…”

The mechanism described in the claim exists and is documented by the state itself. The Utah Office of Artificial Intelligence Policy sits inside the Utah Department of Commerce, was created in May 2024, and operates under Utah Code Title 13, Chapter 72. It issues "regulatory mitigation agreements" (RMAs) under the Artificial Intelligence Learning Laboratory Program, which temporarily waive or modify specified state requirements for named companies under state supervision. The first prescribing pilot was with Doctronic. It was approved in October 2025, went live in December 2025, and was publicly announced on January 6, 2026. It covers renewals only, for roughly 190 to 192 commonly prescribed chronic-condition medications such as those for hypertension, diabetes and thyroid disease. Initial prescriptions must still come from a human clinician. Painkillers, injectables and ADHD medications were excluded at the outset, and butalbital and flecainide were removed from the formulary after launch. The pilot is explicitly phased. In Phase 1, a licensed physician reviews every AI-generated renewal before it goes to a pharmacy. In Phase 2, physician review becomes retrospective for a further cohort. Later stages reduce review further. Advancement is not automatic: it requires the Office's approval, and the trigger was revised so each medication group advances once it reaches 250 refills in that group rather than 250 overall. The OAIP's own May 2026 policy memorandum confirms that Phase 1 required physician review of every AI-generated renewal. On October 5, 2026, OAIP and the Division of Professional Licensing announced three additional healthcare RMAs: Nolla Health (Magic Health, Inc.) for AI-issued initial and renewal prescriptions for topical acne treatment in adults 18 and over; August AI for chronic-condition renewals; and Expect Fitness for virtual physical therapy. The Nolla agreement is narrow: mild to moderate acne only, topical creams and gels, excluding severe acne, oral acne medication and isotretinoin. Its first stage requires two physicians to review each prescription before pharmacy submission, and any reduction in oversight requires written state approval. The agreements explicitly state they are regulatory relief, not a state endorsement of the product. Reporting on October 6 indicated none of the three had launched at that point, while Nolla's own announcement described availability. On accountability, Utah regulators have publicly acknowledged the gap the claim describes. The OAIP director has said the office reads its sandbox authority as insufficient to alter liability rules, that participating companies must carry special liability insurance and may not waive liability, and that a liability bill is being drafted. The state also added third-party auditing of company claims in October 2026. On the FDA: no evidence was found that the FDA is a participant in, source for, or approver of these pilots. Reporting identifies FDA jurisdiction over these tools as an unresolved open question. Separate FDA activity exists on AI-enabled device software and clinical decision support software, but that is not the authority under which Utah's pilots operate. States regulate the practice of medicine; the FDA regulates devices and drugs. Opposition is documented. The Utah Medical Licensing Board wrote to Commerce on April 20, 2026 asking for suspension of the Doctronic agreement, saying it had not been consulted and that proceeding risked patient harm. Commerce declined on April 21, 2026. The American Medical Association has also raised concerns that renewals are not routine administrative checkboxes.